Singapore Markets close in 7 hrs 29 mins

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.1400-0.0100 (-0.87%)
At close: 04:00PM EDT

NeuBase Therapeutics, Inc.

350 Technology Drive
Third Floor
Pittsburgh, PA 15219
United States
646 450 1790

Full-time employees33

Key executives

NameTitlePayExercisedYear born
Dr. Dietrich A. Stephan Ph.D.Founder, CEO & Chairman713.83kN/A1970
Dr. William Roland Mann MBA, Ph.D.Pres & COO470.4kN/A1961
Mr. Todd P. BranningCFO & Sec.N/AN/A1970
Dr. Curt Bradshaw Ph.D.Chief Scientific OfficerN/AN/A1965
Mr. Alan Scrivner J.D.Gen. CounselN/AN/AN/A
Ms. Shannon McCarthyChief People OfficerN/AN/AN/A
Dr. Sandra Rojas-Caro M.D.Head of R&D and Chief Medical OfficerN/AN/A1970
Dr. Robert J. Zamboni Ph.D.Chief of Preclinical Devel. & Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Corporate governance

NeuBase Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.